ArticleOxford medical case reports2025
Signet ring cell carcinoma of the ampulla of Vater: case series.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary pancreatic signet ring cell carcinoma: molecular mechanisms and advances in clinical diagnosis and treatment.World journal of surgical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signet ring cell carcinomas (SRCC) are aggressive neoplasms with poor prognoses, commonly found in the stomach, colon, and small intestine. However, their occurrence in the Ampulla of Vater is rare and their origin remains unclear. Among 163 cases of surgically treated ampullary carcinomas, we observed 4 cases (2.4%) of SRCC with jaundice being the primary clinical manifestation, followed by weight loss and abdominal pain. Duodenoscopy played a pivotal role in the diagnosis. Anatomopathological findings are detailed, emphasizing immuno-histological lineage and lymph node involvement. Two cases underwent adjuvant treatment (GemCap and Folfirinox), with follow-up periods ranging from 18 to 64 months. We review the literature, highlighting the importance of radical surgery, lymph node involvement, and systemic treatment in the survival of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.